A mechanistic modeling platform of SGLT2 inhibition: Implications for type 1 diabetes
- PMID: 36912425
- DOI: 10.1002/psp4.12956
A mechanistic modeling platform of SGLT2 inhibition: Implications for type 1 diabetes
Abstract
Type 1 diabetes mellitus (T1DM) is an autoimmune disease characterized by abnormally high blood glucose concentrations due to dysfunction of the insulin-producing beta-cells in the pancreas. Dapagliflozin, an inhibitor of renal glucose reabsorption, has the potential to improve often suboptimal glycemic control in patients with T1DM through insulin-independent mechanisms and to partially mitigate the adverse effects associated with long-term insulin administration. In this work, we have adapted a systems pharmacology model of type 2 diabetes mellitus to describe the T1DM condition and characterize the effect of dapagliflozin on short- and long-term glycemic markers under various treatment scenarios. The developed platform serves as a quantitative tool for the in silico evaluation of the insulin-glucose-dapagliflozin crosstalk, optimization of the treatment regimens, and it can be further expanded to include additional therapies or other aspects of the disease.
This article is protected by copyright. All rights reserved.
Similar articles
-
Sodium-glucose cotransporter 2 inhibition does not improve the acute pressure natriuresis response in rats with type 1 diabetes.Exp Physiol. 2023 Mar;108(3):480-490. doi: 10.1113/EP090849. Epub 2023 Jan 15. Exp Physiol. 2023. PMID: 36644793
-
Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus.J Clin Pharmacol. 2022 Oct;62(10):1227-1235. doi: 10.1002/jcph.2062. Epub 2022 May 2. J Clin Pharmacol. 2022. PMID: 35403243 Free PMC article.
-
A model-based approach to investigating the relationship between glucose-insulin dynamics and dapagliflozin treatment effect in patients with type 2 diabetes.Diabetes Obes Metab. 2021 Apr;23(4):991-1000. doi: 10.1111/dom.14305. Epub 2021 Jan 25. Diabetes Obes Metab. 2021. PMID: 33368935 Clinical Trial.
-
Dapagliflozin: glucuretic action and beyond.Pharmacol Res. 2014 Apr;82:34-9. doi: 10.1016/j.phrs.2014.03.008. Epub 2014 Apr 3. Pharmacol Res. 2014. PMID: 24705156 Review.
-
[Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes].Med Clin (Barc). 2013 Sep;141 Suppl 2:36-43. doi: 10.1016/S0025-7753(13)70062-9. Med Clin (Barc). 2013. PMID: 24444523 Review. Spanish.